{
    "clinical_study": {
        "@rank": "3337", 
        "arm_group": [
            {
                "arm_group_label": "Arm 1", 
                "arm_group_type": "Experimental", 
                "description": "Low Dose - SkQ1"
            }, 
            {
                "arm_group_label": "Arm 2", 
                "arm_group_type": "Experimental", 
                "description": "High Dose - SkQ1"
            }, 
            {
                "arm_group_label": "Arm 3", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo - SkQ1 (Vehicle)"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate whether SkQ1 ophthalmic solutions are safe and\n      effective compared to placebo for the treatment of the signs and symptoms of dry eye\n      syndrome."
        }, 
        "brief_title": "A Clinical Study to Assess the Safety and Efficacy of an Ophthalmic Solution (SkQ1) in the Treatment of Dry Eye Syndrome", 
        "condition": "Keratoconjunctivitis Sicca", 
        "condition_browse": {
            "mesh_term": [
                "Dry Eye Syndromes", 
                "Keratoconjunctivitis Sicca", 
                "Keratoconjunctivitis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Be male or female of any race, at least 18 years of age\n\n          -  Have provided written informed consent\n\n          -  Have a reported history of dry eye syndrome\n\n          -  Have a history of use or desire to use eye drops for dry eye\n\n        Exclusion Criteria:\n\n          -  Have any clinically significant eye findings that require therapeutic treatment or\n             may interfere with study parameters\n\n          -  Have previously had LASIK surgery within the last 12 months\n\n          -  Have used Restasis\u00ae within 30 days of Visit 1\n\n          -  Be a woman who is pregnant, nursing or planning a pregnancy\n\n          -  Be unwilling to submit a urine pregnancy test if of childbearing potential\n\n          -  Have a known allergy and/or sensitivity to the test article or its components,\n             including the preservative benzalkonium chloride\n\n          -  Be currently enrolled in an investigational drug or device study or have used an\n             investigational drug or device within 30 days of Visit 1\n\n          -  Have a condition or be in a situation which the investigator feels may put the\n             subject at significant risk, may confound the study results, or may interfere\n             significantly with the subject's participation in the study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "90", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 17, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02121301", 
            "org_study_id": "13-110-0006"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Arm 1", 
                    "Arm 2"
                ], 
                "intervention_name": "SkQ1", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Arm 3", 
                "intervention_name": "Placebo SkQ1 (Vehicle)", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Dry Eye", 
            "Dry Eye Syndrome", 
            "SkQ1", 
            "KCS", 
            "Keratoconjunctivitis"
        ], 
        "lastchanged_date": "May 20, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Andover", 
                    "country": "United States", 
                    "state": "Massachusetts"
                }
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Phase 2, Single-Center, Randomized, Double-Masked, Placebo Controlled Clinical Study to Assess the Safety and Efficacy of SkQ1 Ophthalmic Solution in the Environment and During Challenge in the CAE(SM) Model for the Treatment of Dry Eye Syndrome", 
        "other_outcome": {
            "measure": "Number of participants with Adverse events", 
            "safety_issue": "Yes", 
            "time_frame": "Day 29"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Fluorescein Staining", 
                "safety_issue": "No", 
                "time_frame": "Day 29"
            }, 
            {
                "measure": "Worst Dry Eye Symptom", 
                "safety_issue": "No", 
                "time_frame": "Day 29"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02121301"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Mitotech, SA", 
        "sponsors": {
            "collaborator": {
                "agency": "ORA, Inc.", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Mitotech, SA", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}